Back to medications
Medication monograph

risankizumab

Monoclonal AntibodiesInterleukin-23 InhibitorsImmunosuppressantsAntipsoriaticsInterleukin-23 Antagonist

Clinical reference

Product monograph

SKYRIZI- risankizumab-rzaa kitSKYRIZI- risankizumab-rzaa injection

Brands & formulations

Family members

SKYRIZI

Marketed
150 MGSUBCUTANEOUSSOLUTION[ "risankizumab" ]
Product monograph

SKYRIZI

Marketed
150 MGSUBCUTANEOUSSOLUTION[ "risankizumab" ]
Product monograph

SKYRIZI

Marketed
360 MGSUBCUTANEOUSSOLUTION[ "risankizumab" ]
Product monograph

SKYRIZI

Marketed
60 MGINTRAVENOUSSOLUTION[ "risankizumab" ]
Product monograph

SKYRIZI

Marketed
180 MGSUBCUTANEOUSSOLUTION[ "risankizumab" ]
Product monograph

Classification

Chemical class
Monoclonal Antibodies, Interleukin-23 Inhibitors
Clinical class
Immunosuppressants, Antipsoriatics
Banks class
Interleukin-23 Antagonist